|
Robert Drakas, PhD
President
ShangPharma Innovation
|
Dr. Robert Drakas is President of ShangPharma Innovation, a healthcare investment firm that specializes identifying early-stage gems that can advance quickly with the right combination of funding, scientific expertise, and operational support. Dr. Drakas brings more than 20 years of experience in pharmaceutical and biotechnology organizations. Prior to joining ShangPharma Innovation, Dr. Drakas was executive director business development ChemPartner Inc., a leading contract research organization providing services for the biopharmaceutical industry. Earlier in his career, Dr. Drakas held increasing levels of responsibility at Merck Inc. as part of Cancer Research Department and later in operations as part of External Basic Research Department. He received a B.S. degree in biology from the University of Scranton, an M.S. in biochemistry from Drexel University and a Ph.D. in molecular pharmacology from Thomas Jefferson University. Dr. Drakas is board member of Blue Oak Therapeutics, Azkarra Therapeutics, ShangPharma Innovation, Rila Therapeutics, and board observer for Evrys Bio.